Our global Pharmaceuticals portfolio includes more than 50 key marketed products, many of which are innovative leaders in their therapeutic areas. In 2014 we received a total of 13 approvals in the United States, Europe and Japan.
Novartis cardiovascular-metabolic therapeutic teams are passionate about research, development and quality manufacturing of novel therapies and solutions to reduce the burden of diseases in communities around the world. We focus our efforts on diseases that negatively affect the heart, kidney, liver and blood vessels with the goal of better patient outcomes.
Novartis is reimagining the treatment and prevention of visual impairment and blindness. By working to push the boundaries of medicine and technology, we aim to develop life-changing gene therapies, next-generation pharmaceuticals, and transformative technologies for diseases and conditions spanning every area of eye disease, from front to the back of the eye.
Building upon our strong heritage in meeting the unmet needs of Primary Care patients, Novartis is focused on improving the lives of the hundreds of millions of people with respiratory diseases. We remain committed to providing the right drug to the right patient at the right time to treat chronic obstructive pulmonary disease (COPD) and severe allergic asthma — both major public health issues.
Novartis has a strong 60-year history in neuroscience. We currently offer patients and physicians a large drug portfolio encompassing Multiple Sclerosis, Alzheimer’s disease, Parkinson’s Disease, Epilepsy and ADHD, and have a promising pipeline in Multiple Sclerosis, Alzheimer’s disease and Neuromuscular therapies. In our research, we leverage advances in human genetics, new imaging technologies and other novel approaches to better understand brain disorders and continue bringing pioneering drugs to patients worldwide.
Immunology and Dermatology
Our Immunology and Dermatology franchise is transforming patients’ lives by preventing progressive illnesses and successfully treating co-morbidities in the Specialty Dermatology, Rheumatology and Transplantation fields, where there are remaining high unmet medical needs.
Novartis Oncology is a leader in driving the practice of precision oncology treatment. Precision oncology is the evolving understanding of how cancers develop on a genomic level and our ability to develop drugs that hone in on those targets – ultimately leading to better patient outcomes. Our research, driven by a distinctive scientific and clinical strategy, focuses on unmet medical needs and disease pathways.